Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?
Paola Papaldo(Cancer Institute (WIA)), Francesco Cognetti(Apple (Israel)), Alessandra Fabi(Agostino Gemelli University Polyclinic), Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Fabiana Letizia Cecere, Paolo Carlini(National Cancer Institute)
Cited by 2
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
|Journal of Clinical Oncology|2020|226